NTRK2 and lung carcinoma: Five of these lung cancer patients had novel NTRK2 fusions with intronic breakpoints that would likely have been missed if using a DNA NGS targeted panel (Supplementary Table S2), potentially leading to first-line immune checkpoint inhibitor therapy with decreased efficacy in the presence of a co-occurring oncogenic driver.